Sagimet Biosciences Inc.

SGMT Nasdaq SEC CIK 1400118
Follow Sagimet Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$19.1M −48.3% vs same quarter last year
EPS, diluted −$0.31 +22.5% vs same quarter last year
Operating cash flow −$12.1M −19% vs same quarter last year
Operating income −$21.6M −50.5% vs same quarter last year
Net income by quarter
−$16.2M
−$18.2M
−$10.4M
−$12.9M
−$9.6M
−$10.7M
−$14M
−$19.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income5 fiscal years
−$60M−$40M−$20M$0FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$51M
FY24−$45.6M
FY23−$27.9M
FY22−$30.5M
FY21-